We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+5.05%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.58B
AUM Growth
+$636M
Cap. Flow
+$643M
Cap. Flow %
17.97%
Top 10 Hldgs %
40.4%
Holding
113
New
37
Increased
33
Reduced
14
Closed
23

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$210M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$166M
3
RGEN icon
Repligen
RGEN
+$118M
4
ARWR icon
Arrowhead Research
ARWR
+$87M
5
IMCR icon
Immunocore
IMCR
+$70.6M

Top Sells

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$191M
2
TERN
Terns Pharmaceuticals
TERN
+$144M
3
DXCM icon
DexCom
DXCM
+$84.6M
4
MRK icon
Merck
MRK
+$81.6M
5
TYRA icon
Tyra Biosciences
TYRA
+$76.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GPCR icon
101
Structure Therapeutics
GPCR
$3.44B
– –
-35,000
Closed -$2.43M
JAZZ icon
102
Jazz Pharmaceuticals
JAZZ
$15.8B
– –
-290,000
Closed -$49.3M
LNTH icon
103
Lantheus
LNTH
$6.59B
– –
-360,000
Closed -$24M
MIRM icon
104
Mirum Pharmaceuticals
MIRM
$6.38B
– –
-66,000
Closed -$5.21M
DFTX
105
Definium Therapeutics
DFTX
$5.55B
– –
-637,000
Closed -$8.53M
MRK icon
106
Merck
MRK
$316B
– –
-775,000
Closed -$81.6M
PEN icon
107
Penumbra
PEN
$12.7B
– –
-50,000
Closed -$15.5M
QQQ icon
108
PUT
Invesco QQQ Trust
QQQ
$469B
– –
-350,000
Closed -$215M
RZLT icon
109
Rezolute
RZLT
$473M
– –
-1,686,000
Closed -$3.98M
STRO icon
110
Sutro Biopharma
STRO
$416M
– –
-243,000
Closed -$2.81M
ZYME icon
111
Zymeworks
ZYME
$1.6B
– –
-865,000
Closed -$22.8M
LENZ
112
LENZ Therapeutics
LENZ
$157M
– –
-275,000
Closed -$4.4M
UPB
113
Upstream Bio Inc
UPB
$349M
– –
-720,000
Closed -$19.5M
1 2 3 4
5

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return

Vestal Point Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Vestal Point Capital held 113 positions worth $3.58B, up 22% from $2.94B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Vestal Point Capital deployed $643M of net new capital in Q1 2026, opening 37 new positions and adding to 33 existing holdings. Its largest new stake was Neurocrine Biosciences: 1,250,000 shares worth $165M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $144M trimmed.

  • Vestal Point Capital's largest Q1 2026 buy was Neurocrine Biosciences: 1,250,000 shares worth $165M.
  • Vestal Point Capital added most to Revolution Medicines in Q1 2026, an estimated $210M increase.
  • Vestal Point Capital's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $144M.
  • Vestal Point Capital fully exited Arcellx in Q1 2026, selling an estimated $191M.
  • Vestal Point Capital's ten largest holdings make up 40% of its $3.58B portfolio in Q1 2026.
  • Vestal Point Capital opened 37 new positions and closed 23 in Q1 2026.
  • Vestal Point Capital's portfolio value rose 22% quarter-over-quarter to $3.58B.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.